Detalles de la búsqueda
1.
The 3-D conformational shape of N-naphthyl-cyclopenta[d]pyrimidines affects their potency as microtubule targeting agents and their antitumor activity.
Bioorg Med Chem
; 29: 115887, 2021 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33310545
2.
Discovery of amide-bridged pyrrolo[2,3-d]pyrimidines as tumor targeted classical antifolates with selective uptake by folate receptor α and inhibition of de novo purine nucleotide biosynthesis.
Bioorg Med Chem
; 27(23): 115125, 2019 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31679978
3.
Structure based drug design and in vitro metabolism study: Discovery of N-(4-methylthiophenyl)-N,2-dimethyl-cyclopenta[d]pyrimidine as a potent microtubule targeting agent.
Bioorg Med Chem
; 26(9): 2437-2451, 2018 05 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-29655610
4.
Discovery of ARD-2051 as a Potent and Orally Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer.
J Med Chem
; 66(13): 8822-8843, 2023 07 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-37382562
5.
Discovery of ARD-1676 as a Highly Potent and Orally Efficacious AR PROTAC Degrader with a Broad Activity against AR Mutants for the Treatment of AR + Human Prostate Cancer.
J Med Chem
; 66(18): 13280-13303, 2023 Sep 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-37683104
6.
Therapeutic Strategies to Target the Androgen Receptor.
J Med Chem
; 65(13): 8772-8797, 2022 07 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-35786895
7.
[Evaluation of Air Pollution Characteristics and Air Quality Improvement Effect in Beijing and Chengdu].
Huan Jing Ke Xue
; 42(8): 3622-3632, 2021 Aug 08.
Artículo
en Zh
| MEDLINE | ID: mdl-34309249
8.
Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer.
J Med Chem
; 64(18): 13487-13509, 2021 09 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-34473519
9.
Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer.
J Med Chem
; 64(17): 12831-12854, 2021 09 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34431670
10.
Selectively Targeting Tropomyosin Receptor Kinase A (TRKA) via PROTACs.
J Med Chem
; 63(23): 14560-14561, 2020 12 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33206509
11.
Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands.
J Med Chem
; 62(24): 11218-11231, 2019 12 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-31804827
12.
Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer.
J Med Chem
; 62(2): 941-964, 2019 01 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-30629437
13.
MCL-1 inhibition in cancer treatment.
Onco Targets Ther
; 11: 7301-7314, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30425521
14.
Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression.
J Med Chem
; 61(15): 6685-6704, 2018 Aug 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-30019901
15.
The coronary anomaly: right coronary artery originates from the mid left anterior descending artery.
J Invasive Cardiol
; 22(9): E166-7, 2010 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-20814058
Resultados
1 -
15
de 15
1
Próxima >
>>